Ophthalmology

Inflammatory eye disorders

Questions discussed in this category

In a patient with isolated HLA B27+ anterior uveitis, how long would you continue immunosuppressive therapy?

The patient has no extraocular features of a spondyloarthropathy and is on methotrexate. No active eye disease for past 1 year.

1 Answer available

What would be your approach to a patient with Scleroderma/Myositis overlap syndrome (+anti-Ku) and active inflammatory eye disease despite high dose mycophenolate?

2 Answers available

How would you approach management of incidentally identified unilateral retinal vasculitis with subsequent labs revealing +P-ANCA?

Patient is asymptomatic. Labs showed +P-ANCA 1:160. Negative MPO and PR3.

2 Answers available

How do you approach the use of hydroxychloroquine in patients with a history of visual field defect from another cause such as macular degeneration or diabetic retinopathy?

3 Answers available

How would you manage scleritis perforans in a patient with seropositive rheumatoid arthritis/scleroderma overlap?

Patient has failed methotrexate and adalimumab.

2 Answers available

What is your approach to immunosuppression in patients with recurrent peripheral ulcerative keratitis or marginal keratitis who have active disease despite steroid therapy and no current evidence of rheumatologic disease?

Is the approach different from uveitis immunosuppression?

4 Answers available

What do you use to treat uveitis refractory to conventional synthetic DMARDs and TNF inhibitors?

Are IL-17 or IL-23 inhibitors helpful?

5 Answers available

How would you treat uveitis in a patient with a history of cutaneous T cell lymphoma?

Patient was previously well controlled on methotrexate, which was discontinued during cancer treatment.

1 Answer available

Do you extrapolate from uveitis treatment pathways when managing other inflammatory eye conditions such as atypical serpiginous choroiditis?

2 Answers available

Are there any situations in which you would consider starting steroid-sparing agents at the outset for patients with scleritis without any evidence of systemic rheumatic disease?

2 Answers available

Papers discussed in this category

Ophthalmology, 2015-05

Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.

Retina,

LONG-TERM OUTCOMES OF RITUXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS POSTERIOR UVEITIS REFRACTORY TO CONVENTIONAL IMMUNOSUPPRESSIVE THERAPY.

Ophthalmic Res, 2018 Apr 10

Cyclophosphamide or Rituximab Treatment of Scleritis and Uveitis for Patients with Granulomatosis with Polyangiitis.

Dev Ophthalmol, 2012 Apr 17

Rituximab for noninfectious uveitis.

Arthritis Rheumatol, 2019 Aug 12

Long-Term Outcome of Ustekinumab Therapy for Behçet's Disease.

American journal of ophthalmology, 2017-11

Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis.

Int J Environ Res Public Health, 2021 Aug 01

Relationship of Hydroxychloroquine and Ophthalmic Complications in Patients with Type 2 Diabetes in Taiwan.

Related Topics in Ophthalmology